Étiquette : pharmacologie

Cannabinoïds and cancer: causation, remediation, and palliation, Wayne Hall et al., 2005

Cannabinoïds and cancer: causation, remediation, and palliation Wayne Hall, MacDonald Christie, David Currow Lancet Oncology, 2005, 6, 35–42 http://oncology.thelancet.com   This review discusses three different associations between cannabinoids and cancer. First, it assesses evidence that smoking of cannabis preparations may cause cancers of the aerodigestive and respiratory system. There have been case reports of upper-respiratory-tract cancers in young adults who smoke cannabis, but evidence from a few epidemiological cohort studies and case-control studies is inconsistent. Second, there is mixed evidence on the effects of THC and other cannabinoids on cancers: in some in vitro and in vivo studies THC and some synthetic cannabinoids have had [...]

Lire la suite

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics, R. L. Carhart-Harris and K. J. Friston, 2019

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics R. L. Carhart-Harris and K. J. Friston Pharmacological Reviews, 2019,  71, 316–344 https://doi.org/10.1124/pr.118.017160   Significance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . 317 I. Introduction. . . . . . . . . . . . . . . . . . . . . . . . .  [...]

Lire la suite

Disruptive Psychopharmacology, Jama Psychiatry, June 2019

Disruptive Psychopharmacology Boris D. Heifets, MD, PhD1; Robert C. Malenka, MD, PhD2 JAMA Psychiatry. Published online June 26, 2019. doi:10.1001/jamapsychiatry.2019.1145 The paucity of medications with novel mechanisms for the treatment of mental illnesses combined with the delayed response to currently available medications has led to great excitement about the potential therapeutic utility of previously demonized drugs, which offer the hope of generating rapid symptom reductions in some of the sickest patients. Within the past 2 years, the US Food and Drug Administration approved esketamine for treatment-resistant depression and 2 compounds that are still on the US Drug Enforcement Administration’s most restrictive schedule, 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, [...]

Lire la suite

CANNABIS PEER REVIEW 1964-2016, Over 650 Peer Reviewed Reports & Studies On Cannabis, 2017

CANNABIS PEER REVIEW 1964-2016 Over 650 Peer Reviewed Reports & Studies On Cannabis A Free Jeff Prager Publication Health benefits, cancer fighting qualities and many other medicinal advantages can be attributed to the Cannabis Plant. Likewise, diseases and disorders are also related to smoking, vaping and ingesting components of the Cannabis Plant. Cannabis users should be aware and well informed regarding both the positive effects and the negative consequences of regular Cannabis use and this eBook accomplishes that goal by employing over 400 current peer reviewed reports and studies—their findings— with active hyper links to each report. A Free Jeff Prager No-Copyright Publication for [...]

Lire la suite

Medical Cannabis : Effects on Opioid and Benzodiazepine Requirements for Pain Control, Megan O’Connel et al., 2019

Medical Cannabis : Effects on Opioid and Benzodiazepine Requirements for Pain Control.  Megan O’Connell, PharmD, Megan Sandgren, PharmD, MS, BCPS, Leah Frantzen, PharmD, BCPS, Erika Bower, PharmD, BCACP, Brian Erickson, MD Annals of Pharmacotherapy, 2019 May 25:1060028019854221. doi: 10.1177/1060028019854221. PMID : 31129977 Abstract BACKGROUND : There is currently little evidence regarding the use of medical cannabis for the treatment of intractable pain. Literature published on the subject to date has yielded mixed results concerning the efficacy of medical cannabis and has been limited by study design and regulatory issues. OBJECTIVE: The objective of this study was to determine if the use of medical [...]

Lire la suite

Cannabis Pharmacy. The Practical Guide to Medical marijuana, Michael Backes, 2014

Cannabis Pharmacy. The Practical Guide to Medical marijuana Authoritative, evidence-based information, plus advice on treating dozens of ailments and conditions Michael Backes, foreword by Andrew Weil, MD Black Dog & Leventhal Publishers, New York, 2014   Foreword by Andrew Weil, M.D. From the perspective of someone who has studied traditional therapies as a career, it is surprising that cannabis ever left our medicine cabinets, since the plant has been used for millennia in cultures throughout the world as a curative for ailments of both mind and body. In 1942, the American Medical Association (AMA) fought to keep it as part of the U.S. Pharmacopeia. In spite [...]

Lire la suite

Marijuana and the Cannabinoids, Edited by Mahmoud A. ElSohly, 2007

Marijuana and the Cannabinoids Edited by Mahmoud A. ElSohly, PhD, Humana Press, Totowa, New Jersey, USA, 2007 www.humanapress.com 1. Cannabinoids. I. ElSohly, Mahmoud A. II. Series. [DNLM: 1. Cannabinoids. 2. Cannabis. QV 77.7 M33515 2006] QP801.C27M355 2006 615'.7827--dc22 333 pages, Preface Although primarily used today as one of the most prevalent illicit leisure drugs, the use of Cannabis sativa L., commonly referred to as marijuana, for medicinal purposes has been reported for more than 5000 years. Marijuana use has been shown to create numerous health problems, and, consequently, the expanding use beyond medical purposes into recreational use (abuse) resulted in control of the drug through international treaties. Much research has been [...]

Lire la suite

WHO Expert Committee on Drug Dependence. Critical Review. Cannabis and cannabis resin, 2018

WHO Expert Committee on Drug Dependence. Critical Review Cannabis and cannabis resin © World Health Organization 2018   Cannabis and cannabis resin Section 1: Chemistry 1. Substance identification ............................................................................................... 4 1.1 International Nonproprietary Name (INN) .............................................................................................. 4 1.2 Chemical Abstract Service (CAS) registry number ................................................................................... 4 1.3 Other chemical names ............................................................................................................................ 4 1.4 Trade names ........................................................................................................................................... 4 Cannabis 1.4.1 plant .................................................................................................................................. 4 1.4.2 Cannabis resin .................................................................................................................................. 5 1.5 Street names ........................................................................................................................................... 5 1.5.1 Cannabis plant .................................................................................................................................. 5 1.5.2 Cannabis resin .................................................................................................................................. 5 1.6 Physical appearance ............................................................................................................................... 6 1.6.1 Cannabis plant .................................................................................................................................. 6 1.6.2 Cannabis resin .................................................................................................................................. 6 1.7 WHO review history ................................................................................................................................ 7 2. Chemistry ..................................................................................................................... 8 2.1 Name ...................................................................................................................................................... 8 2.2 Chemical name ....................................................................................................................................... 8 2.2.1 IUPAC name: ..................................................................................................................................... 8 2.2.2 CA index [...]

Lire la suite

Usage médical du cannabis et des cannabinoïdes. Questions et réponses à l’intention des décideurs politiquesObservatoire européen des drogues et des toxicomanies (2019), Office des publications de l’Union européenne, Luxembourg, Décembre 2018

Usage médical du cannabis et des cannabinoïdes Questions et réponses à l’intention des décideurs politiques Observatoire européen des drogues et des toxicomanies (2019), Office des publications de l’Union européenne, Luxembourg Décembre 2018 PDF ISBN 978-92-9497-406-8 doi:10.2810/25727 TD-06-18-186-FR-N Table des matières : 5 Introduction 6 Quels sont les sujets abordés dans ce rapport? 7 Qu’entend-on par usage médical de cannabis et de cannabinoïdes? 11 PARTIE 1 Quelles données scientifiques attestent-elles d’un usage médical du cannabis et des cannabinoïdes? 11 Comment évaluer l’efficacité des médicaments? 12 Quels sont les données scientifiques récentes de l’efficacité du cannabis et des cannabinoïdes en tant que médicaments? 15 Quels sont les risques pour la santé associés à l’usage médical du [...]

Lire la suite

Dream over life : Psychedelic terphenyl derivative induce hallucination via cannabinoid receptor 1, F.A. Fauzi et al., 2018

Dream over life : Psychedelic terphenyl derivative induce hallucination via cannabinoid receptor 1 F.A. Fauzi, M.S. Goh, S.A.T.T. Johari, F. Hashim, M.F.N. Hassim The International Fundamentum Sciences Symposium 2018 IOP Publishing IOP Conf. Series: Materials Science and Engineering 440 (2018) 012045 doi:10.1088/1757-899X/440/1/012045   Abstract. For ages, natural psychedelic resources have been used by ancient tribes for religious inspiration. In modern medicine, these compounds were prescribed to relieve severe distress and depression on cancer patients. Despite medical benefit, abuse of these compounds have become prevalent in our modern society. These compounds usually interacted withcannabinoid receptor 1 (CNR1) on neuron cell causing hallucination, and on other cell-types. In this [...]

Lire la suite